98 related articles for article (PubMed ID: 6825122)
1. Phase II trial of the dopaminergic inhibitor pimozide in previously treated melanoma patients.
Neifeld JP; Tormey DC; Baker MA; Meyskens FL; Taub RN
Cancer Treat Rep; 1983 Feb; 67(2):155-7. PubMed ID: 6825122
[TBL] [Abstract][Full Text] [Related]
2. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma.
Dorval T; Palangie T; Jouve M; Garcia-Giralt E; Israel L; Falcoff E; Schwab D; Pouillart P
Cancer; 1986 Jul; 58(2):215-8. PubMed ID: 3719515
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
[TBL] [Abstract][Full Text] [Related]
4. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.
Bedikian AY; Papadopoulos NE; Kim KB; Vardeleon A; Smith T; Lu B; Deitcher SR
Melanoma Res; 2008 Dec; 18(6):400-4. PubMed ID: 19011511
[TBL] [Abstract][Full Text] [Related]
5. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
Whitehead RP; Moon J; McCachren SS; Hersh EM; Samlowski WE; Beck JT; Tchekmedyian NS; Sondak VK;
Cancer; 2004 Apr; 100(8):1699-704. PubMed ID: 15073859
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of 4'-epi-doxorubicin in patients with advanced malignant melanoma.
Berman E; Casper ES; Howard J; Wittes RE
Cancer Treat Rep; 1984 Apr; 68(4):679-80. PubMed ID: 6585272
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of chlorozotocin in malignant melanoma: a Southeastern Cancer Study Group report.
Van Amburg AL; Presant CA; Burns D
Cancer Treat Rep; 1982 Jun; 66(6):1431-3. PubMed ID: 6211234
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen in metastatic malignant melanoma.
Meyskens FL; Voakes JB
Cancer Treat Rep; 1980 Jan; 64(1):171-3. PubMed ID: 7379053
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma.
Olver IN; Byrne MJ; Walpole E; Vorobiof D; Jacobs C; Maart K; Hewitt S; McAdam G; Pouget JC; Pinel MC
Eur J Cancer; 2007 Aug; 43(12):1829-32. PubMed ID: 17631996
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
Stopeck AT; Jones A; Hersh EM; Thompson JA; Finucane DM; Gutheil JC; Gonzalez R
Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803
[TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of the efficacy of modern first, second, and third line regimes of chemotherapy in patients with disseminated cutaneous melanoma].
Akimov MA; Gershanovich ML
Vopr Onkol; 2001; 47(4):428-35. PubMed ID: 11710284
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Vestermark LW; Larsen S; Lindeløv B; Bastholt L
Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
[TBL] [Abstract][Full Text] [Related]
19. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of tamoxifen in patients with metastatic malignant melanoma.
Telhaug R; Klepp O; Børmer O
Cancer Treat Rep; 1982 Jun; 66(6):1437. PubMed ID: 7083247
[No Abstract] [Full Text] [Related]
[Next] [New Search]
